Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF | V.TLT.W

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > $tltff The FDA wants an option that has rates better then

<< Previous

Bullboard Posts

Next >>

Comment by stocksnbonds458on Apr 12, 2022 8:32pm

155 Views

Post# 34598772

RE:RE:RE:$tltff The FDA wants an option that has rates better then

Perhaps a silly question, but say for example TLT's product was on the market and a patient knew they had a 70% chance be CR at 90 days, and only a 19% chance of being CR at 360 days. Knowing this could be a potential oucome, would not all patients request to continue to receive this treatment on a continuous basis , such that the likelihood of a return of cancer is unlikely? In other words, in the real would not treatments of TLD1433 provide 70% of all patients a CR for the rest of their lives?

<< Previous

Bullboard Posts

Next >>

High-quality lithium projects in Argentina with drilling underway